title: A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid.
abstract: The effects of the cyclooxygenase inhibitors indomethacin and carprofen on the enhancement of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis by dietary linoleate have been compared in female Sprague-Dawley rats. Indomethacin and carprofen, 0.004% and 0.02% (w/w) in the diet, respectively, were fed to rats receiving 20% fat diets containing 0.5, 4 or 12% linoleate starting 7 days after administration of 5 mg DMBA i.g. Indomethacin was shown to have a marked inhibitory effect on mammary tumorigenesis in rats fed the 4 and 12% linoleate diets, but did not alter tumorigenesis in rats fed the 0.5% linoleate diet. In contrast, carprofen was not inhibitory in any of these dietary groups, or in a separate experiment in which a 5% fat--3% linoleate diet was fed. The effect of each drug on prostaglandin E2 (PGE2) levels in normal mammary glands enriched in epithelial cells after a 3-week pretreatment with 17 beta-estradiol and progesterone was also investigated. Carprofen was shown to reduce PGE2 levels to a similar or greater extent than indomethacin at each level of linoleate in the diet. These data demonstrate that a reduction in PGE2 synthesis in the mammary epithelium does not correlate with inhibition of mammary tumorigenesis, and that other factors, including possible alterations in other products of the arachidonic acid cascade, are responsible for this inhibitory effect.
authors.affiliation: Department of Breast Surgery, New York State Department of Health, Roswell Park Memorial Institute, Buffalo 14263.
authors.forename: C A
authors.initials: CA
authors.lastname: Carter
authors.forename: M M
authors.initials: MM
authors.lastname: Ip
authors.forename: C
authors.initials: C
authors.lastname: Ip
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002227:Carbazoles / Q000494:pharmacology*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D004041:Dietary Fats / Q000494:pharmacology*; D005228:Fatty Acids, Essential / Q000494:pharmacology*; D005260:Female; D007213:Indomethacin / Q000494:pharmacology*; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000473:pathology*; D011448:Prostaglandin Antagonists / Q000494:pharmacology*; D011458:Prostaglandins E / Q000097:blood / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002227:Carbazoles; D004041:Dietary Fats; D005228:Fatty Acids, Essential; D011448:Prostaglandin Antagonists; D011458:Prostaglandins E; D015127:9,10-Dimethyl-1,2-benzanthracene; C007005:carprofen; D007213:Indomethacin